Beta Drugs Limited has informed the Exchange about General Updates
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs has responded to NSE's observations on its earlier EOGM corrigendum by sharing detailed shareholding pattern and allotment details for a proposed preferential issue. The company is acquiring Nivian Lifesciences through a combination of share swap and cash, issuing a total of 2,83,668 new equity shares of Beta Drugs. Of these, shares against cash consideration account for 3,28,358 Nivian shares (cash inflow of about ₹48.58 crore), while the share-swap portion covers 7,66,177 Nivian shares at a swap ratio of 37 Beta shares for every 100 Nivian shares. Post-issue share count rises from 1,00,94,553 to 1,10,85,872 shares (about 9.8% dilution), with promoter holding dropping from 64.90% to 59.10%. The allotment list includes over 30 individuals, LLPs, and corporate entities.
This is a regulatory clarification rather than a new corporate action — the actual preferential issue and Nivian Lifesciences acquisition were already approved earlier. Existing shareholders face around 5.8 percentage points of promoter-level dilution, but the deal expands the company's footprint in the pharma/lifesciences space. Short-term stock reaction is likely muted as this only provides additional details, not a fresh trigger.